Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
August 12, 2022 7:52 PM 3 min read

Are Rocket Lab's Shares Undervalued?

by BlackBull Markets Benzinga Contributor
Follow
RKLB Logo
RKLBRocket Lab Corp
$72.25-%
Overview

In comparison with perceived market-leader SpaceX, Rocket Lab USA's (NASDAQ:RKLB) valuation is underwhelming. Given its $2.5 billion market capitalization, Rocket Lab is eclipsed by the $127 billion SpaceX. However, analysts believe that assessing Rocket Lab's true worth warrants a look beyond its immediate financial results and into the pieces it is adding to the game.

Looking beyond valuations, Rocket Lab had been operating at a loss for at least the last 12 months. Despite this, it saw its shares grow 26% over the last month. It hit $5.55 on Aug. 4 when its launched a U.S. spy satellite in New Zealand atop its Electron booster. It reached another high on Aug. 8 at $5.60 before closing the day at $5.45.

From a more macro point of view, Rocket Lab’s stock price is traveling in line with other SPAC listings, down 55% for the year-to-date. Which opens the question as to why it is not more in line with defense stocks, such as iShares U.S. Aerospace & Defense ETF (up 1.73% YTD), which appear to be benefiting from the increase in US defense spending. 

NASDAQ:RKLB 1D, with iShares U.S. Aerospace & Defense ETF 

 

Bearish Second-Quarter Forecast 

Rocket Lab is set to announce its results for the quarter ended June 30 on Aug. 11. It expects EBITDA loss to be between $3.5 million and $5.5 million and for its revenue to be somewhere within the $51 million to $54 million range. The company is expected to record normalized loss per share of $0.06.

In the first quarter of 2022, the company recorded adjusted loss of roughly $8.0 million and a 124% year-over-year hike in revenue to $40.7 million. Despite the bearish expectations for the upcoming results, it can be observed that the loss Rocket Lab has been reporting becomes less than the previous period. The company may not be far from breaking even at the rate it is going. 

 

Retaining Confidence 

The Aug. 4/5 launch for the U.S. National Reconnaissance Office managed to boost confidence for the company, enough to lift its stocks to $5.55. The mission marked the 146th satellite deployment from the Electron booster to date. But as noted above, Rocket Lab may not have experienced the full impact of the increase in US defense spending.

Additionally, the company is currently developing Neutron, a reusable booster planned to be 40 meters high and to have a 7 meter diameter. It is a medium-lift rocket designed for the deployment of mega-constellations, human spaceflight and deep space missions. The first flight of Neutron is planned for 2024.

The reusable aspect of the Neutron could be a make or break product for Rocket Lab. If successful, the reusable Neutron can carry out more launches and generate more revenue over a definite period. It can eventually lead to better gross profits as it will help reduce production costs.

In this respect Rocket Lab may offer an asymmetric risk/reward at current valuation due to potential profitability gains, both through diversification and with attempts to reuse the Electron booster. 

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
Marketscontributors
RKLB Logo
RKLBRocket Lab Corp
$72.25-%
Overview
Comments
Loading...